A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.
Ben Garmezy, MD
Advertisement
Articles by Ben Garmezy, MD
A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.
The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.
Manojkumar Bupathi, MD, MS, and Ben Garmezy, MD, discuss how to optimize treatment approaches for genitourinary cancers through evaluation of real-world data, sequencing strategies, and toxicity management while working to bridge care disparities between community and academic settings.
Advertisement
Latest Updated Articles
Episode 1: NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder CancerPublished: March 4th 2025 | Updated:
- Episode 2: Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
Published: March 5th 2025 | Updated:
- Episode 3: Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma
Published: March 7th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will ESMO 2025 Data Shape the Future of Genitourinary Cancer Care?
2
Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma
3
Real-World Data From IMS: Promising Results in Relapsed/Refractory Multiple Myeloma
4
Leveraging Novel Software to Further Improve Personalized Cancer Care
5
